Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (IV) for reimbursement as a monotherapy treatment option for the treatment of patients with HER2 positive early breast cancer.

This is written in the approval document as:

HER2 positive early breast cancer (EBC).

Citation

Trastuzumab (IV) Monotherapy - 21 days, 2022, version number 7, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6330/200_v7_Trastuzumab_21days.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (1) HER2-positive Invasive Breast Carcinoma Trastuzumab